Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis.
Level 3 - non-randomized controlled study
Systematic review and meta-analysis of longitudinal and case-control observational studies
PubMed 33933505 · doi:10.1016/j.neubiorev.2021.04.031
What was done
Authors conducted a systematic review and meta-analysis evaluating the relationship between anticholinergic drug exposure and subsequent risk of dementia. They pooled data from 14 longitudinal and case-control studies comprising a total of 1,564,181 participants, analyzing all-cause dementia, Alzheimer's disease, dose-response relationships, and specific drug classes.
What was found
The abstract reports no numerical effect estimates (such as odds ratios, relative risks, or confidence intervals). Anticholinergic drug use was associated with an increased risk of both all-cause dementia and Alzheimer's disease across low and high drug burdens, demonstrating a dose-dependent relationship. By drug class, antiparkinsonian, urological, and antidepressant medications were associated with increased dementia risk, whereas cardiovascular and gastrointestinal agents showed potentially protective associations.
Why it matters
Anticholinergic medications are widely prescribed in older adults, and these findings support considering cumulative anticholinergic burden as a potentially modifiable risk factor for cognitive decline.
Limits
The abstract provides qualitative directions of effect but omits all point estimates, confidence intervals, and measures of statistical heterogeneity. Because all underlying data come from observational studies (cohort and case-control), findings are vulnerable to residual confounding, reverse causation (protopathic bias), and confounding by indication.
Cited by
- context Daily long-term use of diphenhydramine found in over-the-counter PM sleep aids can lead directly to Alzheimer's disease.